Mangoceuticals, Inc. Common Stock (NASDAQ:MGRX) — Market Cap & Net Worth
Market Cap & Net Worth: Mangoceuticals, Inc. Common Stock (MGRX)
Mangoceuticals, Inc. Common Stock (NASDAQ:MGRX) has a market capitalization of $6.08 Million ($6.08 Million) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28167 globally and #5721 in its home market, demonstrating a -0.05% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mangoceuticals, Inc. Common Stock's stock price $0.56 by its total outstanding shares 16288797 (16.29 Million). Review Mangoceuticals, Inc. Common Stock debt and liabilities to assess the company's total debt and financial obligations.
Mangoceuticals, Inc. Common Stock Market Cap History: 2023 to 2026
Mangoceuticals, Inc. Common Stock's market capitalization history from 2023 to 2026. Data shows change from $67.68 Million to $9.07 Million (-75.11% CAGR).
Index Memberships
Mangoceuticals, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #817 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2610 of 3165 |
Weight: Mangoceuticals, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mangoceuticals, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mangoceuticals, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
64.27x
Mangoceuticals, Inc. Common Stock's market cap is 64.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $67.68 Million | $731.49K | -$9.21 Million | 92.52x | N/A |
| 2024 | $39.58 Million | $615.87K | -$8.71 Million | 64.27x | N/A |
Competitor Companies of MGRX by Market Capitalization
Companies near Mangoceuticals, Inc. Common Stock in the global market cap rankings as of August 1, 2026.
Key companies related to Mangoceuticals, Inc. Common Stock by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #980 globally with a market cap of $27.24 Billion USD.
- Pro Medicus Ltd (AU:PME): Ranked #1931 globally with a market cap of $11.99 Billion USD ( AU$16.95 Billion AUD).
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2123 globally with a market cap of $10.63 Billion USD.
- Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM): Ranked #2675 globally with a market cap of $7.62 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #980 | Veeva Systems Inc Class A | NYSE:VEEV | $27.24 Billion | $203.78 |
| #1931 | Pro Medicus Ltd | AU:PME | $11.99 Billion | AU$162.21 |
| #2123 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $10.63 Billion | $59.71 |
| #2675 | Tempus AI, Inc. Class A Common Stock | NASDAQ:TEM | $7.62 Billion | $43.87 |
Mangoceuticals, Inc. Common Stock Historical Marketcap From 2023 to 2026
Between 2023 and today, Mangoceuticals, Inc. Common Stock's market cap moved from $67.68 Million to $ 9.07 Million, with a yearly change of -75.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $9.07 Million | -24.72% |
| 2025 | $12.05 Million | -69.55% |
| 2024 | $39.58 Million | -41.52% |
| 2023 | $67.68 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Mangoceuticals, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.08 Million USD |
| MoneyControl | $6.08 Million USD |
| MarketWatch | $6.08 Million USD |
| marketcap.company | $6.08 Million USD |
| Reuters | $6.08 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mangoceuticals, Inc. Common Stock
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also p… Read more